USMCA will stunt potentially lifesaving innovation

The new trade agreement represents progress for international trade, but crucially, it weakens protections for the biopharma industry

USMCA will stunt potentially lifesaving innovationIn December, the United States, Mexico and Canada signed a new trade agreement (USMCA) in Mexico City. The agreement represents progress for international trade, but crucially, it weakens protections for the biopharma industry, as the final version of the deal removed provisions that would have extended the exclusivity (essentially, the period of time when brand-name…

National pharmacare can hurt patients more than it helps

Will likely result in reduced access to new drugs, and delay research and development

National pharmacare can hurt patients more than it helpsThe federal government’s pharmacare advisory council released a report last week outlining the “foundational” elements of a national plan. And Tuesday’s federal budget may include more details. Unfortunately, there’s a lot of misinformation and misunderstanding regarding core aspects of the pharmacare debate. Given that proponents in Canada often cite government-funded pharmacare programs in the United…